Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 1/20 | 0.70 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.70 |
| ▸ | EGFR | P00533 | 14/20 | 0.63 |
| ▸ | KRAS | P01116 | 1/20 | 0.63 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.56 |
| ▸ | TNF | P01375 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3000657 | 1.00 | GALR3 (0.70) | GALR3NR2F2EGFRKRASSOS1 | |
| SCHEMBL157422 | 0.89 | GALR3 (0.56) | GALR3NR2F2EGFRKRASSOS1 | |
| SCHEMBL31505701 | 0.85 | GALR3 (0.72) | GALR3NR2F2EGFRKRASSOS1 | |
| SCHEMBL31505705 | 0.85 | GALR3 (0.72) | GALR3NR2F2EGFRKRASSOS1 | |
| SCHEMBL13283262 | 0.85 | GALR3 (0.72) | GALR3NR2F2EGFRKRASSOS1 | |
| SCHEMBL24577013 | 0.84 | GALR3 (0.70) | GALR3NR2F2EGFRKRASSOS1 | |
| SCHEMBL9921344 | 0.84 | GALR3 (0.70) | GALR3NR2F2EGFRKRASSOS1 | |
| SCHEMBL24576524 | 0.84 | GALR3 (0.70) | GALR3NR2F2EGFRKRASSOS1 | |
| SCHEMBL13170943 | 0.84 | GALR3 (0.70) | GALR3NR2F2EGFRKRASSOS1 | |
| SCHEMBL644489 | 0.84 | GALR3 (0.70) | GALR3NR2F2EGFRKRASSOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6653305-B2 | For therapy of tumoral diseases, diseases of the lungs and respiratory tract | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-11-25 | — | — | US | disclosed |
| EP-1315717-A1 | QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | Boehringer Ingelheim Pharma KG (DE) | 2003-06-04 | — | — | EP | disclosed |
| US-20020077330-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-06-20 | — | — | US | disclosed |
| WO-2002018373-A1 | QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077330-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NR3C2, CYP11B2 | GALR3 1425/4885NR2F2 1096/4885EGFR 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.